Analysts expect Immucell Corp /De/ to report revenue of 5.72 M for Q1 22, against a range of 5.51 M to 5.94 M. The most recent reported quarter, Q4 21, came in at 5.40 M, a 6.5% beat against the 5.07 M consensus.
| Metric | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 |
|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 4.11 M | 4.54 M | 5.20 M | 5.40 M | - | - | - | - |
| High Estimate | 5.47 M | 3.63 M | 3.96 M | 5.27 M | 5.94 M | 6.22 M | 7.77 M | 7.86 M |
| Low Estimate | 4.94 M | 3.31 M | 3.67 M | 4.87 M | 5.51 M | 5.30 M | 6.45 M | 6.96 M |
| Consensus Estimate | 5.21 M | 3.47 M | 3.81 M | 5.07 M | 5.72 M | 5.76 M | 7.11 M | 7.41 M |
Analysts expect Immucell Corp /De/ to report earnings per share of -0.01 for Q1 22, against a range of -0.01 to -0.01. The most recent reported quarter, Q4 21, came in at -0.01 , in line with the -0.01 consensus.
| Metric | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 |
|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.06 | 0.02 | 0.02 | -0.01 | - | - | - | - |
| High Estimate | 0.05 | -0.08 | -0.06 | -0.01 | -0.01 | 0.07 | 0.08 | 0.04 |
| Low Estimate | 0.05 | -0.08 | -0.06 | -0.01 | -0.01 | 0.07 | 0.06 | 0.04 |
| Consensus Estimate | 0.05 | -0.08 | -0.06 | -0.01 | -0.01 | 0.07 | 0.07 | 0.04 |
Pull Wall Street consensus for Immucell Corp /De/ (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=ICCC&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "ICCC", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=ICCC&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();